Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events

Washington University School of Medicine41 enrolled

Overview

This study seeks to determine which Loa loa antigens are released into circulation when infected individuals are treated with ivermectin.

A cohort of up to 50 participants with Loa loa microfilarial levels between 5,000 and 18,000 per ml/blood will be treated with ivermectin in an inpatient setting. Participants will be monitored for treatment-related adverse events for seven days post-treatment, and will have blood drawn on days 0, 1, 2, 3, and 7 post-treatment to assess for microfilarial load, cytokine, and antigen levels.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Loiasis

Interventions

IvermectinDRUG

single dose, 150 ug/kg

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Loa loa blood microfilariae of between 5,000 - 18,000 per mL Exclusion Criteria: * known allergy to ivermectin; severe comorbidities

Locations (1)

Centre de Recherche sur les Filarioses et autres Maladies Tropicales (CRFilMT)

Yaoundé, Cameroon

Outcomes

Primary Outcomes

Cross-reactive Antigenemia

N of participants with detectable Loa loa antigens in sera that cross-react with diagnostic tests for lymphatic filariasis (Filariasis Test Strip) on either day 1, 2, 3, or 7 post-treatment

Time frame: 7 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.